Search Results - "Köchert, K."

Analysis of single-nucleotide polymorphisms (SNPs) in the phase III RESORCE trial of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) by Köchert, K., Meinhardt, G., Bruix, J., Teufel, M.

Get full text

The IL-15 cytokine system provides growth and survival signals in Hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells by Ullrich, K, Blumenthal-Barby, F, Lamprecht, B, Köchert, K, Lenze, D, Hummel, M, Mathas, S, Dörken, B, Janz, M

Get full text

2013 Analysis of biomarkers in circulating tumor DNA from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC): Correlation with clinical outcome by Teufel, M, Kalmus, J, Rutstein, M, Köchert, K, Seidel, H, Reischl, J, Skubula, A, Vonk, R, Wilhelm, S, Kobina, S, Qin, S, Xu, R, Kim, T.W, Li, J

Get full text

Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma by Wurster, K D, Hummel, F, Richter, J, Giefing, M, Hartmann, S, Hansmann, M-L, Kreher, S, Köchert, K, Krappmann, D, Klapper, W, Hummel, M, Wenzel, S-S, Lenz, G, Janz, M, Dörken, B, Siebert, R, Mathas, S

“…Apart from its unique histopathological appearance with rare tumor cells embedded in an inflammatory background of bystander cells, classical Hodgkin lymphoma…”
Get full text

Serum glucocorticoid-regulated kinase 1 ( ) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells by Fagerli, U-M, Ullrich, K, Stühmer, T, Holien, T, Köchert, K, Holt, R U, Bruland, O, Chatterjee, M, Nogai, H, Lenz, G, Shaughnessy, J D, Mathas, S, Sundan, A, Bargou, R C, Dörken, B, Børset, M, Janz, M

“…Multiple myeloma (MM) is a paradigm for a malignant disease that exploits external stimuli of the microenvironment for growth and survival. A thorough…”
Get full text

High-level expression of Mastermind-like 2 contributes to aberrant activation of the NOTCH signaling pathway in human lymphomas by Köchert, K, Ullrich, K, Kreher, S, Aster, J C, Kitagawa, M, Jöhrens, K, Anagnostopoulos, I, Jundt, F, Lamprecht, B, Zimber-Strobl, U, Stein, H, Janz, M, Dörken, B, Mathas, S

“…Inappropriate activation of the NOTCH signaling pathway, for example, by activating mutations, contributes to the pathogenesis of various human malignancies…”
Get full text

Exploratory analysis of baseline microsatellite instability (MSI) status in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) or placebo in the phase 3 CORRECT trial by Köchert, K., Beckmann, G., Teufel, M.

Get full text

701PAnalysis of single-nucleotide polymorphisms (SNPs) in the phase III RESORCE trial of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) by Köchert, K, Meinhardt, G, Bruix, J, Teufel, M

Get full text

465P Single nucleotide polymorphism (SNP) analysis identifies potential prognostic and predictive biomarker in patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib in the phase III CORRECT trial by Battaglin, F., Zhang, W., Skubala, A., Arai, H., Wang, J., Soni, S., Wang, Y.A., Köchert, K., Schulz, A., Teufel, M., Millstein, J., Lenz, H.J.

Get full text

Protein biomarkers as predictors of outcome with regorafenib (REG) in patients (pts) with hepatocellular carcinoma (HCC) in the RESORCE trial by Teufel, M., Köchert, K., Meinhardt, G., Finn, R.S., Llovet, J.M., Bruix, J.

Get full text

Circulating miRNA biomarkers predicting regorafenib (REG) clinical benefit in patients with hepatocellular carcinoma (HCC) in the RESORCE trial by Teufel, M., Seidel, H., Köchert, K., Meinhardt, G., Finn, R.S., Llovet, J.M., Bruix, J.

Get full text

Tumor gene expression signatures of BCR/PI3K dependence in association with copanlisib monotherapy activity in heavily pretreated patients with indolent NHL and follicular lymphoma by Liu, L., Köchert, K., Seidel, H., Garcia-Vargas, J., Childs, B.H., Follows, G., Bouabdallah, K., Dreyling, M., Peña, C.

Get full text